Arbutus Biopharma (ABUS) Price & Analysis

Compare

1,264 Followers

ABUS Stock Chart & Stats

$4.41

-$0.15(-4.40%)

At close: Jan 08 4:00 PM EST

$4.41

-$0.15(-4.40%)

Day’s Range― - ―

52-Week Range$2.71 - $5.10

Previous CloseN/A

Volume149.14K

Average Volume (3M)984.95K

Market Cap

$801.99M

Enterprise Value$781.58M

Total Cash (Recent Filing)$93.70M

Total Debt (Recent Filing)$922.00K

Price to Earnings (P/E)―

Beta0.16

Next Earnings

Feb 26, 2026

EPS Estimate

-0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding192,324,020

10 Day Avg. Volume1,009,647

30 Day Avg. Volume984,946

Financial Highlights & Ratios

PEG Ratio0.64

Price to Book (P/B)6.23

Price to Sales (P/S)98.35

P/FCF Ratio-9.33

Enterprise Value/Market Cap0.97

Enterprise Value/Revenue53.51

Enterprise Value/Gross Profit-246.24

Enterprise Value/Ebitda-17.51

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.19

Revenue Forecast (FY)$13.63M

Bulls Say, Bears Say

Bulls Say

Financial ManagementArbutus ended 2024 with $123M in cash and highlighted a 'continued focus on efficient deployment of financial resources and personnel.'

Legal ProceedingsA positive outcome to the Markman hearing was viewed as favorable for Arbutus.

Product DevelopmentAnalyst recommends a Buy rating, affirming confidence in the potential of imdusiran as a core component for achieving a functional cure in HBV.

Bears Say

Clinical TrialsArbutus has discontinued the planned IM-PROVE III Phase 2a trial of imdusiran plus anti-PD-L1 antibody durvalumab prior to initiation.

Legal ChallengesArbutus and partner Genevant expand their LNP legal activity against Moderna globally.

Restructuring CostsArbutus anticipates a one-time restructuring charge of ~$11M-$13M in 1Q25.

Arbutus Biopharma News

Arbutus Biopharma reports Q3 EPS (4c), consensus (5c)

Reports Q3 revenue $529k, consensus $1.31M. “The strength of our third quarter performance reflects our disciplined focus on...

23d ago

ABUS

Arbutus Biopharma Reports Q3 2025 Financial Results

Arbutus Biopharma ( ($ABUS) ) has released its Q3 earnings. Here is a breakdown of the information Arbutus...

17d ago

ABUS

Arbutus Biopharma Reports Strong Q3 Financial Results

Arbutus Biopharma ( ($ABUS) ) has issued an announcement. On November 13, 2025, Arbutus Biopharma reported its third...

23d ago

ABUS

ABUS Upcoming Earnings Report: What to Expect?

Arbutus Biopharma (ABUS) is scheduled to report 3rd quarter earnings on 11/05/2025. Regarding Q3 estimates, Wall Street analysts...

1M ago

ABUS

Arbutus Biopharma’s Long-Term Hepatitis B Study: A Potential Game-Changer for Investors

Arbutus Biopharma (($ABUS)) announced an update on their ongoing clinical study. Arbutus Biopharma is conducting a long-term follow-up...

1M ago

ABUS

Arbutus Biopharma Showcases Data at Liver Meeting 2025

Arbutus Biopharma ( ($ABUS) ) has issued an update. On October 7, 2025, Arbutus Biopharma announced that four...

2M ago

ABUS

Arbutus Biopharma to present imdusiran, AB-101 data at The Liver Meeting 2025

Arbutus Biopharma (ABUS) announced that three abstracts featuring imdusiran data and one abstract featuring AB-101 data, have been...

2M ago

ABUS

Arbutus Biopharma’s Patent Ruling in Pfizer Lawsuit

The latest update is out from Arbutus Biopharma ( ($ABUS) ). On September 9, 2025, the U.S. District...

3M ago

ABUS

Arbutus Biopharma Reports Strong Revenue Growth in Q2 2025

Arbutus Biopharma ( ($ABUS) ) has released its Q2 earnings. Here is a breakdown of the information Arbutus...

4M ago

ABUS

Arbutus Biopharma Appoints New Board Member Amid Strong Q2

The latest announcement is out from Arbutus Biopharma ( ($ABUS) ). On August 4, 2025, Anuj Hasija resigned...

4M ago

ABUS

Arbutus Biopharma reports Q2 EPS 1c vs (11c) last year

Reports Q2 revenue $10.7M, consensus $2.21M. “We delivered a strong quarter, marked by positive quarterly earnings resulting from...

4M ago

ABUS

Arbutus Biopharma’s AB-101 Study: A Potential Game-Changer in Chronic Hepatitis B Treatment

Arbutus Biopharma (($ABUS)) announced an update on their ongoing clinical study. Arbutus Biopharma is conducting a study titled...

5M ago

ABUS

Arbutus Biopharma Ends Partnership with Qilu Pharmaceutical

The latest update is out from Arbutus Biopharma ( ($ABUS) ). On June 20, 2025, Arbutus Biopharma and...

5M ago

ABUS

Arbutus Biopharma reacquires Greater China rights to imdusiran, forms SAB

Arbutus Biopharma (ABUS) announced that it has reacquired China rights to its lead compound, imdusiran, from Qilu Pharmaceutical....

5M ago

ABUS

ABUS FAQ

What was Arbutus Biopharma’s price range in the past 12 months?

Arbutus Biopharma lowest stock price was $2.71 and its highest was $5.10 in the past 12 months.

What is Arbutus Biopharma’s market cap?

Arbutus Biopharma’s market cap is $801.99M.

When is Arbutus Biopharma’s upcoming earnings report date?

Arbutus Biopharma’s upcoming earnings report date is Feb 26, 2026 which is in 82 days.

How were Arbutus Biopharma’s earnings last quarter?

Arbutus Biopharma released its earnings results on Nov 13, 2025. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.03 by -$0.01.

Is Arbutus Biopharma overvalued?

According to Wall Street analysts Arbutus Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arbutus Biopharma pay dividends?

Arbutus Biopharma does not currently pay dividends.

What is Arbutus Biopharma’s EPS estimate?

Arbutus Biopharma’s EPS estimate is -0.03.

How many shares outstanding does Arbutus Biopharma have?

Arbutus Biopharma has 192,324,020 shares outstanding.

What happened to Arbutus Biopharma’s price movement after its last earnings report?

Arbutus Biopharma reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.03. Following the earnings report the stock price went down -5.785%.

Which hedge fund is a major shareholder of Arbutus Biopharma?

Currently, no hedge funds are holding shares in ABUS

Arbutus Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-45.88%

Trailing 12-Months

Asset Growth

-30.43%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arbutus Biopharma

Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of viral diseases, particularly hepatitis B (HBV) and other viral infections. The company's core products include a range of RNA interference (RNAi) therapies and other novel antiviral compounds aimed at addressing unmet medical needs in the field of infectious diseases. Arbutus leverages its proprietary technology platforms to advance its drug candidates through various stages of clinical development.